Invitrogen to Acquire Bio Asia for $8M To Expand Company’s China Presence

Invitrogen announced Wednesday that it will acquire Bio Asia, a Chinese reagent supplier, for up to $8 million in cash, and plans to invest more than $20 million in China over the next five years, the company said.

Bio Asia, which is based in Shanghai and has branches in Beijing and Guangzhou, as well as 18 sales offices across China, provides sequencing reagents and custom R&D services. The company, which was founded in 1999, has approximately $5 million in revenues.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers have treated an X-linked genetic disease affecting three babies in utero, Stat News reports.

The Associated Press reports that the US Centers for Disease Control and Prevention is beefing up sequencing as a tool to investigate foodborne illnesses.

Researchers have sequenced samples from ancient toilets to study past eating habits and health, NPR reports.

In Nature this week: ash dieback disease fungal genome, and more.